PFE: Sigvotatug Vedotin Also Not Able to Knock Off Docetaxel in the 2L NSCLC Setting; Broader SV Development Program Continues, Including in 1L NSCLC

Research evidence excerpt

PFE: Sigvotatug Vedotin Also Not Able to Knock Off Docetaxel in the 2L NSCLC Setting; Broader SV Development Program Continues, Including in 1L NSCLC

GLOBAL BIOPHARMACEUTICALS

PFIZER INC. June 22, 2026

Equity Valuation and Risks: For valuation methodology and risks associated with covered companies or price targets for covered companies, please

see the most recent company-specific research report at https://guggenheimlibrary.bluematrix.com/client/library.jsp, contact the primary analyst or your

Guggenheim Securities, LLC representative, or email GSResearchDisclosures@guggenheimpartners.com.

RATINGS DISTRIBUTIONS FOR GUGGENHEIM SECURITIES:

IB Serv./ Past 12Mos.

Rating Category Count Percent Count Percent

BUY 295 75.26% 80 27.12%

HOLD 96 24.49% 6 6.25%

SELL 1 0.26% 0 0.00%

Guggenheim Securities Research assigns Buy, Neutral, Sell ratings for covered securities. Such assignments equate to Buy, Hold and Sell for the purposes

of the above Rating Distribution Disclosure required by FINRA Rule 2241.

OTHER DISCLOSURES

This research is for our clients and prospective clients only. This research was prepared by personnel who are associated with both Guggenheim Securities,

LLC (a FINRA-registered broker-dealer, “Guggenheim Securities”) and Guggenheim Securities Research Services, LLC (an investment adviser, “GSRS,”

and together with Guggenheim Securities, “Guggenheim”). If you are paying separately for this research, it is being provided to you by GSRS. Otherwise, it

is being provided by Guggenheim Securities. Guggenheim does not create tailored or personalized research and all research provided by Guggenheim is

impersonal advice. Other than disclosures relating to Guggenheim and our affiliates, this research is based on current public information that we consider